MedCap AB (OSTO:MCAP) Other Long-Term Liabilities: kr271 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MCAP MedCap AB OSTO:MCAP
91 GF Score
Price kr560.50
GF Value kr573.02
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is MedCap AB Other Long-Term Liabilities?

MedCap AB OSTO:MCAP -1.41% 91 Other Long-Term Liabilities is kr271 Mil as of Jun. 2026. GuruFocus rates OSTO:MCAP with a GF Score™ of 91/100 and a GF Value™ of kr573.02 (Fairly Valued). The stock has 1 warning sign investors should review.

MedCap AB's other long-term liabilities for the quarter that ended in Jun. 2026 was kr271 Mil.

MedCap AB's quarterly other long-term liabilities declined from Dec. 2025 (kr272 Mil) to Mar. 2026 (kr260 Mil) but then increased from Mar. 2026 (kr260 Mil) to Jun. 2026 (kr271 Mil).

MedCap AB's annual other long-term liabilities declined from Dec. 2023 (kr100 Mil) to Dec. 2024 (kr74 Mil) but then increased from Dec. 2024 (kr74 Mil) to Dec. 2025 (kr272 Mil).

MedCap AB Other Long-Term Liabilities Related Terms

MedCap AB Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for MedCap AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB Other Long-Term Liabilities Chart

MedCap AB Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.40 44.70 99.80 74.30 271.90

MedCap AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.30 213.00 271.90 260.00 270.70
OSTO:MCAP
91GF Score
MedCap AB OSTO:MCAP
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedCap AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of kr271 Mil mean?
MedCap AB (OSTO:MCAP) has a Other Long-Term Liabilities of kr271 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MedCap AB and its competitors.
Is MedCap AB's Other Long-Term Liabilities too high?
MedCap AB's current Other Long-Term Liabilities is kr271 Mil. Overall, MedCap AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Other Long-Term Liabilities compare to ABT and SYK?
MedCap AB's Other Long-Term Liabilities of kr271 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MedCap AB and its competitors. MedCap AB's current Other Long-Term Liabilities is kr271 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr573.02, compared to a current price of kr560.50 — trading 2.2% below its estimated fair value. The current Other Long-Term Liabilities is kr271 Mil. MedCap AB's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current Other Long-Term Liabilities is kr271 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (OSTO:MCAP) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr560.50 is trading 2.2% below its estimated GF Value™ of kr573.02. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for OSTO:MCAP:

  • Other Long-Term Liabilities: kr271 Mil
  • GF Value™: kr573.02 vs. price of kr560.50 (2.2% below fair value)
  • GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MedCap AB Business Description

Other Exchanges MCAPs:UK61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
91GF Score

Get the complete analysis for OSTO:MCAP

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr560.50
Price
kr573.02
GF Value